Elevance Health Inc. (ELV)

FairStock Score: 50/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am looking at Elevance Health as a large health benefits company with 96,129 employees, operating health plans and Carelon services. Scale and BlueCard relationships help, but health insurance is regulated and competitive, so the moat is modest, not wide. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $50.5B, net income $1.5B, and diluted EPS $6.71. A year earlier, in fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $49.8B, net income $1.7B, and diluted EPS $7.72. Sales edged up; profits and per-share earnings fell. For the full year, FY2025 revenue was $199.1B, net income $5.7B, and diluted EPS $25.21, versus FY2024 revenue of $177.0B, net income of $6.0B, and diluted EPS of $25.68. The pattern is slower profit growth than revenue growth. FairStock's calculations put ROE at 11.13%, ROCE at 3.83%, and debt-to-equity at 0.69; Altman Z-Score is 1.49 and Piotroski F-Score is 6/9. Free cash flow is $6.3B, a 6.8% FCF yield, which is respectable. At the close on 2026-10-13, the price was $425.27, giving a P/E of 18.82 and P/B of 2.05. The Graham Number is $324.43, so the price is about 31.08% above that conservative value. FairStock calls it a SLOW GROWER: profit 4.4% a year over five years, revenue 10.3%. I see a fair-to-full price for a business that must prove margin recovery and better returns on capital.

In plain English: Elevance Health sells health insurance and related health services to individuals, employers, and government programs like Medicare and Medicaid. It is a large business that generates cash, but recent profits have slipped and profitability looks only modest. At $425.27 on 2026-10-13, the shares look full rather than cheap compared with the company's profits and accounting value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer